Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergey Shcherbinin

Showing results (21-30 of 74) with videos related to

Pageof 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 7, 2016
Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer DiseaseSergey Shcherbinin, Adam J Schwarz, Abhinay Joshi, et al.
Pharmaceutics|March 29, 2023
Preclinical PET Imaging and Toxicity Study of a <sup>68</sup>Ga-Functionalized Polymeric Cardiac Blood Pool AgentKatayoun Saatchi, François Bénard, Navjit Hundal, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersKay Hoong Chow, Tongrong Wang, Ilke Tunali, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Predicting regional tau accumulation with machine learning-based tau-PET and advanced radiomicsSaima Rathore, Ixavier A Higgins, Jian Wang, et al.
Neuroimage. Clinical|November 7, 2024
Tau-network mapping of domain-specific cognitive impairment in Alzheimer's diseaseYing Luan, Anna Rubinski, Davina Biel, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 22, 2021
Donanemab (LY3002813) dose-escalation study in Alzheimer's diseaseStephen Loucian Lowe, Brian A Willis, Anne Hawdon, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2023
Donanemab exposure and efficacy relationship using modeling in Alzheimer's diseaseIvelina Gueorguieva, Brian A Willis, Laiyi Chua, et al.
Clinical Pharmacology and Therapeutics|February 22, 2023
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's DiseaseIvelina Gueorguieva, Brian A Willis, Laiyi Chua, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 5, 2022
Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementiaDiana Otero Svaldi, Ixavier A Higgins, Karen C Holdridge, et al.
Brain : a Journal of Neurology|March 4, 2016
Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stagesAdam J Schwarz, Peng Yu, Bradley B Miller, et al.
Pageof 8

Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 7, 2016
Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer DiseaseSergey Shcherbinin, Adam J Schwarz, Abhinay Joshi, et al.
Pharmaceutics|March 29, 2023
Preclinical PET Imaging and Toxicity Study of a <sup>68</sup>Ga-Functionalized Polymeric Cardiac Blood Pool AgentKatayoun Saatchi, François Bénard, Navjit Hundal, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersKay Hoong Chow, Tongrong Wang, Ilke Tunali, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Predicting regional tau accumulation with machine learning-based tau-PET and advanced radiomicsSaima Rathore, Ixavier A Higgins, Jian Wang, et al.
Neuroimage. Clinical|November 7, 2024
Tau-network mapping of domain-specific cognitive impairment in Alzheimer's diseaseYing Luan, Anna Rubinski, Davina Biel, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 22, 2021
Donanemab (LY3002813) dose-escalation study in Alzheimer's diseaseStephen Loucian Lowe, Brian A Willis, Anne Hawdon, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2023
Donanemab exposure and efficacy relationship using modeling in Alzheimer's diseaseIvelina Gueorguieva, Brian A Willis, Laiyi Chua, et al.
Clinical Pharmacology and Therapeutics|February 22, 2023
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's DiseaseIvelina Gueorguieva, Brian A Willis, Laiyi Chua, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 5, 2022
Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementiaDiana Otero Svaldi, Ixavier A Higgins, Karen C Holdridge, et al.
Brain : a Journal of Neurology|March 4, 2016
Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stagesAdam J Schwarz, Peng Yu, Bradley B Miller, et al.
Pageof 8